Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Expectations

<< Previous

Bullboard Posts

Next >>

Comment by longrun86on Aug 08, 2022 1:51pm

150 Views

Post# 34879356

RE:RE:RE:RE:RE:Expectations

I should have made a further comment on the EBITDA margin.

The reason why I thought that this would be higher was because of Exelon. As we were/are in a transition period with Exelon, I had expected this to have a temporary (but artificial) impact to margins in the short run.

Mid-to-high teen EBITDA makes sense in the long run.

<< Previous

Bullboard Posts

Next >>

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload